{"id":11397,"date":"2024-08-14T12:42:53","date_gmt":"2024-08-14T12:42:53","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/antipaf\/"},"modified":"2024-12-16T13:05:59","modified_gmt":"2024-12-16T13:05:59","slug":"antipaf","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/antipaf\/","title":{"rendered":"ANTIPAF"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

ANTIPAF<\/strong>-AFNET 2<\/h2>\n\n\n\n
<\/div>\n\n\n\n

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial)<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

Study design<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of days with documented episodes of paroxysmal AF) during a 12-month follow-up as the primary study end point. Four hundred thirty patients with documented paroxysmal AF without structural heart disease were randomized to placebo or 40 mg olmesartan per day.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
Inclusion Criteria<\/strong><\/h5>\n\n\n\n

\"\" Documented paroxysmal atrial fibrillation: ECG documentation of atrial fibrillation at least in one ECG recorded during the last 2 months prior to randomization plus additional ECG recording of sinus rhythm at least 12 hours after the above mentioned ECG documentation.<\/p>\n\n\n\n

\"\" Age \u2265 18<\/p>\n\n\n\n

\"\" Patient informed orally and in writing<\/p>\n\n\n\n

\"\" Written informed consent of the patient<\/p>\n<\/div>\n\n\n\n

\n
Exclusion Criteria<\/strong><\/h5>\n\n\n\n

\"\" Strong clinical evidence for therapy with AT II\/ACE inhibitors<\/p>\n\n\n\n

\"\" AT II\/ACE inhibitor therapy within the last month<\/p>\n\n\n\n

\"\" Therapy with antiarrhythmic agents of class I or class III within the last month, therapy with amiodarone within the last 3 months<\/p>\n\n\n\n

\"\" Direct current (DC) cardioversion within the last 3 months<\/p>\n\n\n\n

\"\" Symptomatic bradycardia<\/p>\n\n\n\n

\"\" Implanted pacemaker or implanted cardioverter\/defibrillator with any antitachycardiac algorithm in use<\/p>\n\n\n\n